Document:

Exhibit
10.2

 

83NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES.

 

WARRANT
TO PURCHASE SHARES OF COMMON STOCK

OF

SAVE
FOODS, INC.

(the
“Corporation”)

 

Number
of Shares of Common Stock of the Corporation, par value $0.0001 each (the “Common Stock”): _____________

 

Issue
Date: ________, 2020

Initial
Exercise Date: _________, 2020.

 

This
warrant to purchase shares of Common Stock (the “Warrant”) certifies that, for value received, ________________
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after _________ , 2020 (the “Initial Exercise Date”), and on or prior to the close
of business 36 (thirty-six) months following the Issue Date (the “Termination Date”), provided that, if such
date is not a Trading Day, the Termination Date should be the immediate following Trading Day but not thereafter, to subscribe
for and purchase from the Corporation, up to ________ shares of Common Stock (the “Warrant Shares”). The purchase
price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Securities
Purchase Agreement (the “Purchase Agreement”), dated ___________, 2020, among the Corporation and the Holder,
as applicable.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Corporation (or such other
office or agency that the Corporation may designate by notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Corporation) of a duly executed facsimile copy or PDF copy submitted by electronic mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Corporation until the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Corporation for cancellation
within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Corporation. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Corporation shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Corporation shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt
of such notice. The Holder, by acceptance of this Warrant, acknowledges and agrees that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 

     

    

 

In
no event will the Corporation be required to net cash settle a Warrant exercise.

 

b)
Exercise Price. The exercise price per Share under this Warrant shall be $1.20, subject to adjustment hereunder (the “Exercise
Price”).

 

c)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Corporation shall cause its transfer agent (the “Transfer Agent”)
to issue the Warrant Shares, and credit the account of the Holder or (B) the Warrant Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered
in the name of the Holder, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise, by the date that is the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Corporation of the Notice of Exercise (such
date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been
exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price is
received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. As used herein, “Standard Settlement Period” means the
standard settlement period, expressed in a number of Trading Days, on the Corporation’s primary Trading Market with respect
to the Shares as in effect on the date of delivery of the Notice of Exercise.

 

    	 

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Corporation shall, at the
request of the Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to
the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Corporation fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(c)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Warrant Shares or Scrip. No fractional Warrant Shares shall be issued upon the exercise of this Warrant.
As to any fraction of a Share that the Holder would otherwise be entitled to purchase upon such exercise, the Corporation shall
be entitled to round down such to the next whole Share.

 

v.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of Warrant Shares, all of which taxes and expenses shall be paid by
the Corporation, and such Warrant Shares shall be issued in the name of the Holder. The Corporation shall pay all applicable fees
and expenses of the Transfer Agent in connection with the issuance of the Warrant Shares hereunder.

 

The
Holder is aware and agree that any tax consequences arising from the grant or exercise of any Warrant from the payment for Warrant
Shares covered thereby or from any other event or act (of the Corporation and/or its Affiliates or the Holder), hereunder, shall
be borne solely by the Holder. The Corporation and/or its Affiliates shall withhold taxes according to the requirements under
the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Holder hereby accept to indemnify
the Corporation and/or its Affiliates and hold them harmless against and from any and all liability for any such tax or interest
or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any
such tax from any payment made to you.

 

The
Holder will not be entitled to receive from the Corporation any Warrant Shares allocated or issued upon the exercise of the Warrant
prior to the full payments of any tax liabilities arising from the Warrants, which were granted to the Holder and/or the Warrant
Shares issued upon the exercise of the Warrants. For the avoidance of doubt, the Corporation shall not be required to release
any share to the Holder until all payments required to be made by the Holder have been fully satisfied.

 

    	 

     

    

 

vi.
Closing of Books. The Corporation will not close its shareholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

Section
3. Certain Adjustments.

 

a)
Share Dividends and Splits. If the Corporation, at any time while this Warrant is outstanding: (i) pays a share dividend
or otherwise makes a distribution or distributions on its Shares or any other equity or equity equivalent securities payable in
Shares (which, for avoidance of doubt, shall not include any Shares issued by the Corporation upon exercise of this Warrant),
as applicable, (ii) subdivides outstanding Shares into a larger number of Shares, as applicable, (iii) combines (including by
way of reverse share split) outstanding Shares into a smaller number of Shares, as applicable, or (iv) issues by reclassification
of Shares, or any shares of capital stock of the Corporation, as applicable, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of Shares, (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of Shares, outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after
the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.

 

    	 

     

    

 

b)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Corporation, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the
Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Shares
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Shares, (iv) the Corporation, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Shares or any compulsory share exchange pursuant to which the
Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or
indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires more than 50% of the outstanding Shares (not including Shares held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares of capital stock
of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable in respect of one Share, in such Fundamental Transaction, and the Corporation shall
apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Shares are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. The Corporation shall cause any successor entity
in a Fundamental Transaction in which the Corporation is not the survivor (the “Successor Entity”) to assume
in writing all of the obligations of the Corporation under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section 3(b) pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the
Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the Shares represented by each Warrant Share acquirable and
receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an exercise price which applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the Shares pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant and the other Transaction Documents referring to the “Corporation” shall refer instead
to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of
the Corporation under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been
named as the Corporation herein.

 

c)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a Share,
as the case may be. For purposes of this Section 3, the number of Shares deemed to be issued and outstanding as of a given date
shall be the sum of the number of Shares (excluding treasury shares, if any) issued and outstanding.

 

    	 

     

    

 

d)
Notice to Holder. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Corporation
shall deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are non-transferable.

 

b)
Warrant Register. The Corporation shall register this Warrant, upon records to be maintained by the Corporation for that
purpose (the “Warrant Register”), in the name of the record Holder hereof.

 

c)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section
5. Miscellaneous.

 

a)
No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a shareholder of the Corporation prior to the exercise hereof as set forth in Section 2(c)(i).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Corporation covenants that upon receipt by the Corporation of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating
to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and
upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Corporation will make and deliver a new
Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c)
Fridays, Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

    	 

     

    

 

d)
Authorized Shares. The Corporation covenants that, during the period the Warrant is outstanding, it will reserve from its
authorized and unissued Shares a sufficient number of shares to provide for the issuance of the Warrant Shares and underlying
Shares upon the exercise of any purchase rights under this Warrant. The Corporation further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are charged with the duty of issuing the Warrant Shares needed for
the Transfer Agent to issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Corporation
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the Shares may
be listed. The Corporation covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges
created by the Corporation in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Purchase Agreement, as applicable.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of the
Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date, if the Corporation willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Corporation shall pay to the Holder
such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’
fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Corporation
shall be delivered in accordance with the notice provisions of the Purchase Agreement, as applicable.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Shares or as a shareholder of the Corporation, whether such liability is asserted
by the Corporation or by creditors of the Corporation.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Corporation agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

    	 

     

    

 

k)
Successors. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors of the Corporation and the successors of Holder.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Corporation
and the Holder.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	 

     

    

 

IN
WITNESS WHEREOF, the Corporation has caused this Warrant to be executed by its officer thereunto duly authorized as of the date
first above indicated.

 

	 	SAVE FOODS, INC.
	 	 	 
	 	By:	          
	 	Name:	 
	 	Title:	 

 

    	 

     

    

 

NOTICE
OF EXERCISE

 

To:
SAVE FOODS, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Corporation pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full in form of United States currency; or

 

(2)
Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

(3)
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

(4)
The Warrant Shares shall be delivered to the Investor

 

____________________________________

 

____________________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity:

 

________________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity:

 

________________________________________________________________________

 

Name
of Authorized Signatory: _____________________________________________________________________

 

Title
of Authorized Signatory: ______________________________________________________________________

 

Date:
_____________Exhibit
10.18

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS THROUGHOUT THIS EXHIBIT.

 

PATENT
LICENSE AGREEMENT

 

This
PATENT LICENSE AGREEMENT (“Agreement”), is dated as of December 1, 2019, made effective as of December 1, 2019
(“Effective Date”), by and between Medigus Ltd., a company organized under the laws of the State of Israel
(“Licensor”) and ScoutCam Ltd., a company organized under the laws of the State of Israel (“Licensee”).
Licensor and Licensee are each referred to herein separately as “Party” and are referred to herein collectively
as the “Parties.”

 

W
I T N E S S E T H:

 

	WHEREAS	 	Licensee
    desires to obtain a license from Licensor to use the patent described in Exhibit A, attached hereto (“Licensed IP”);
    and

 

	WHEREAS	 	Licensor
    is willing to grant such right and license on the terms and conditions set forth herein.

 

NOW,
THEREFORE, the Parties hereby agree as follows:

 

	1.	DEFINITIONS

 

1.1.
Certain Definitions. For purposes of this Agreement, the following terms shall have the meanings specified in this Section
‎1.1:

 

	 	1.1.1.	“Affiliate”
    means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls,
    or is controlled by, or is under common control with, such Person, and the term “control” (including the terms
    “controlled by” and “under common control with”) means the possession, directly or indirectly, of
    the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting
    securities, by contract or otherwise. For purposes of this Agreement, Licensor and Licensee shall not be deemed Affiliates
    of one another.

 

	 	1.1.2.	“IIA”
    means the Israeli Innovation Authority of the Ministry of Economy and Industry of the State of Israel (formerly known as the
    Office of the Chief Scientist).

 

	 	1.1.3.	“Law”
    means any federal, state, local, municipal, foreign or other law (including common law), statute, legislation, constitution,
    code, order, edict, decree, proclamation, treaty, convention, directive, ordinance, rule, regulation, permit, ruling, determination,
    decision, interpretation or other requirement that is issued, enacted, adopted, passed, approved, promulgated, implemented
    or otherwise put into effect by or under the authority of any Governmental Body and is applicable to and binding upon the
    relevant Person.

 

	 	1.1.4.	“Person”
    means (whether or not a capitalized term) any individual, corporation, partnership, limited liability company, firm, joint
    venture, association, joint-stock company, trust, estate, unincorporated organization, Governmental Body or other entity,
    including any party to this Agreement.

 

	 	1.1.5.	“Representative(s)”
    means, with respect to any Person, such Person’s Affiliates and the respective directors, officers, employees, agents,
    consultants, advisors and other representatives, including legal counsel, accountants and financial advisors of such Person
    and its Affiliates, and the successors and assigns of any of the foregoing.

 

	 	1.1.6.	“M&A
    Event” means a merger, acquisition or sale of all or substantially all of the assets of Licensee.

 

	 	1.1.7.	“Products”
    means products, applications, technologies or solutions, relating to the miniature video technology, referred to as ScoutCamTM.

 

    	 

    	-2-

    

 

	2.	PATENT
    LICENSE

 

2.1.
With respect to the patent included in Exhibit A (the “Licensed IP”), Licensor hereby grants Licensee,
subject to the IIA prior approval, a perpetual, non-exclusive, transferable solely upon an M&A Event, royalty free, license
to access, use, improve, develop either by or on behalf of the Licensee, market and sell the Licensed IP, including the right
to any future versions, enhancements, improvements and derivative works of the Licensed IP for the purpose of developing and commercializing
the Products (collectively, the “License”).

 

2.2.
As a condition of the License, Licensor shall not sell, offer to sell or grant any ownership right in the Licensed IP to any potential
direct competitor of Licensee. For the avoidance of doubt, the Licensee does not (and shall not be construed) to limit or restrict
the Licensor’s right to grant any additional licenses relating to the Licensed IP including to non-direct competitors of
Licensee.

 

2.3.
Successors and Assigns. The terms and conditions of the License will bind and inure to the benefit of each of the Parties,
their successors and Affiliates.

 

	3.	REPRESENTATIONS
    AND WARRANTIES

 

3.1.
General. Each Party hereby represents and warrants that it has the full legal right, power, and authority to enter into
this Agreement and to perform its obligations hereunder, that the performance of such obligations will not conflict with or result
in a breach of any agreement to which such Party is a party or is otherwise bound, and that this Agreement is legally binding
upon such representing and warranting Party.

 

3.2.
The License is granted to Licensee on an as-is basis, and all representations and warranties, whether express, implied, statutory
or otherwise, including, without limitation, any implied warranty of merchantability, fitness for a particular purpose or non-infringement,
are hereby disclaimed to the maximum extent permitted by applicable law by Licensor, and Licensee assumes the full risk in connection
therewith.

 

	4.	CONDITION
    OF LICENSE

 

4.1.
Condition Precedent to the Obligation of Each Party. The grant of the License shall be subject to the prior approval of
IIA, to the extent required (the “IIA Approval”). Licensor shall submit as soon as practicable an appropriate request
for the grant of the IIA Approval and will use best efforts to obtain the IIA Approval as soon as possible. In the event that
the IIA Approval is not obtained within ninety (90) days of the Effective Date, Licensee may opt to terminate this Agreement without
any further liability to Licensor.

 

4.2.
IIA Undertaking. As condition of receiving the License, Licensee will be obligated to execute and undertaking in a form
acceptable to Licensor, pursuant to which Licensee agrees to comply with the obligations stipulated by the Law for Encouragement
of Research & Development, 1984.

 

	5.	CONSIDERATION;
    TAXES

 

5.1.
In consideration for the Transferred Assets and Assumed Liabilities Licensee issues Licensor 1,000,000 ordinary shares, no par
value each, of Licensee.

 

5.2.
Any tax consequences arising from the sale and assignment or any other event or act hereunder, shall be borne solely by the Licensor.

 

	6.	MISCELLANEOUS

 

6.1.
Entire Agreement. The Parties hereto acknowledge that this Agreement and each of the exhibits attached hereto set forth
the entire agreement and understanding of the Parties as to the subject matter hereto, and supersedes all prior and contemporaneous
discussions, agreements and writings in respect hereto.

 

    	 

    	-3-

    

 

6.2.
Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State
of Israel, without giving effect to the rules of conflict of laws thereof. Each of the parties hereto irrevocably consents to
the exclusive jurisdiction and venue of any competent court located in Tel Aviv-Jaffa, Israel, in connection with any matter based
upon or arising out of this Agreement or the matters contemplated herein, agrees that process may be served upon them in any manner
authorized by the laws of the State of Israel for such persons and waives and covenants not to assert or plead any objection which
they might otherwise have to such jurisdiction and such process.

 

6.3.
Binding Effect. This Agreement shall be binding upon the Parties immediately upon signing of the Agreement by the Parties,
subject to fulfillment of the conditions in Section 4.

 

6.4.
No Third Party Beneficiaries; Assignment. Nothing in this Agreement shall create or be deemed to create any third party
beneficiary rights in any person or entity not a party to this Agreement, but other than rights expressly granted to Representatives
of a party hereunder. No assignment of this Agreement or of any rights or obligations hereunder may be made (by operation of law
or otherwise) by the Licensor or the Licensee without the prior written consent of the other party hereto and any attempted assignment
without the required consents shall be void; provided, however, that after Closing, either party may assign this Agreement and
any or all rights or obligations hereunder to any Affiliate.

 

6.5.
Amendment and Waivers. This Agreement may be amended, supplemented or changed, and any provision hereof can be waived,
only by written instrument signed by the Parties, or in case of a waiver by the party against whom enforcement of any such amendment,
supplement, modification or waiver is sought. No action taken pursuant to this Agreement, including without limitation, any investigation
by or on behalf of any party, shall be deemed to constitute a waiver by the party taking such action of compliance with any representation,
warranty, covenant or agreement contained herein. The waiver by any party hereto of a breach of any provision of this Agreement
shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach.
No failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other
or further exercise thereof or the exercise of any other right, power or remedy.

 

6.6.
Severability. If any term or other provision of this Agreement is invalid, illegal, or incapable of being enforced by any
law or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long
as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to
any party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as
possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated
to the greatest extent possible.

 

6.7.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and
enforceable against the parties actually executing such counterpart, and all of which together shall be considered one and the
same agreement, it being understood that all parties need not sign the same counterpart. The exchange of an executed Agreement
(in counterparts or otherwise) by facsimile transmission or by electronic delivery in .pdf format or the like shall be sufficient
to bind the parties to the terms and conditions of this Agreement, as an original.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 

    	-4-

    

 

IN
WITNESS WHEREOF, Licensor and Licensee have executed this Patent License Agreement by their respective duly authorized representatives
as of the date first written above.

 

	Medigus
    Ltd.  	 	ScoutCam
    Ltd.
	 	 	 	 	 
	By:	/s/
    Liron Carmel /s/ Tatiana Yosef	 	By:	/s/
    Benad Goldwasser /s/ Yaron Silberman 
	Name:	Liron
    Carmel / Tatiana Yosef	 	Name:	Benad
    Goldwasser / Yaron Silberman
	Title:	CEO
    / CFO	 	Title:	Chairman
    / CEO

 

    	 

    	-5-

    

 

Exhibit
A

 

Licensed
IP

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]